I have been in drug development since 2000 and oligonucleotide nonclinical safety since 2011.

I can help you with nonclinical strategies to derisk safety and regulatory hurdles of your oligo assets. Happy to assist with your regulatory documents and HA interaction preparation.

If you need a review of tox packages to inform safety risk in your DD's, I am there too.